Updated on 21 July 2014
The new transfusion technology will speed up the process reducing the wait-time for patients awaiting the transfusion
Singapore: BioCSL has inked a deal with US-based Immucor to distribute transfusion testing technology in Australia and New Zealand. BioCSL has already started distribution of Immucor's capture antibody detection technology platform and reagents in these two markets.
This platform is designed for cross matching of blood used for transfusion. CSL said that the platform used techniques very different from the commonly used procedures in Australia. It delivered high levels of specificity, reducing the need for additional testing and subsequently reducing the wait-time for patients awaiting a blood transfusion.
The Immucor product range consists of around 2,000 immunohaematology reagents, automated testing devices and Immucor's supporting Immulink software.
Mr Allen Bollands, director for immunohaematology, bioCSL said that the Capture platform would help in maintaining Australia and New Zealand's safety record for blood transfusions. He said that this will help in saving more lives as the testing procedure is quick, more authentic and sensitive.